Clinical Trials & Research
Many of today's most effective standard treatments are based on the results of previous clinical studies, and many cancer patients are now living longer because of progress made through clinical trials. Clinical trials offer high quality cancer care and also allow patients the opportunity to advance scientific knowledge and help future patients. Ongoing research is essential in the fight against cancer, and it is one of the major objectives of the Edwards Comprehensive Cancer Center.
The Charles H. McKown, Jr., MD, Translational Genomic Research Institute (TGRI), which is housed on the third floor of the Edwards Comprehensive Cancer Center, offers the appropriate environment for performing leading-edge cancer research and conducting clinical trials that are helping to shape the future of cancer research — and not just in Huntington.
ChemoID®, the first chemosensitivity assay against both cancer stem cells and bulk of tumor cells for patients, was developed by researchers, physicians and scientists working in the Translational Genomic Research Institute (TGRI) and it is now in use in the United States as well as other countries around the world.
“The goal of cancer research at the TGRI is to directly affect the disease outcome by taking innovative technologies and novel drugs from the bench to the bedside,” said Dr. Pier Paolo Claudio, who was instrumental in developing ChemoID®. “This approach saves lives and reduces healthcare costs. The research we conduct at the TGRI in collaboration with the Edwards Comprehensive Cancer Center will have a far-reaching impact on people suffering with cancer around the world.”
Clinical trials currently available
|CALGB 30901||Randomized Phase II Study of Maintenance Pemetrexed versus Observation for Patients with Malignant Pleural Mesothelioma Without Progression After First-line Chemotherapy|
|CALGB-30607||Randomized, Phase III, Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer.|
|CALGB-30801||A Randomized Ph III Double Blind Trial Evaluating Selective Cox-2 Inhibition in Cox 2 Expressing Advanced NSCLC.|
|E1505||A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB - IIIA Non-Small Cell Lung Cancer (NSCLC).|
|RTOG 1306||A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)|
|S0819||A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC).|
- Page last updated: Jul 3, 2014